postibrutinib 1
outcomes 1
patients 4
mantle 2
cell 4
lymphoma 4
randomized 1
phase 3
ii 2
trial 1
comparing 1
obinutuzumab 1
ga 1
rituximab 1
relapsed 2
cd 2
indolent 2
bcell 1
nonhodgkin 1
final 1
analysis 1
gauss 1
study 3
targeting 1
b 2
receptor 1
signaling 1
ibrutinib 1
diffuse 1
large 1
pro 1
novel 1
anticd 1
monoclonal 1
antibody 1
relapsedrefractory 1
nhl 1
correlation 1
between 1
clinical 1
responses 1
auc 1
pharmacokinetics 1
multicenter 1
bortezomib 1
refractory 1
